ANI Pharmaceuticals deal boosts injectable portfolioANI Pharmaceuticals has added a second specialty injectable product to its pipeline, the first product being Cortrophin gel. Teva launches generic AndroGelTestosterone gel 1.62% had an annual market value of more than $911 million, according to February 2019 IQVIA data. Rite Aid highlights MMR vaccine availability As of April 11, the Centers for Disease Control and Prevention have confirmed 555 cases of measles in the country. Lupin gets FDA green light for generic Prozac Fluoxetine tablets had an annual market value of roughly $68.2 million, according to December 2018 IQVIA data. FDA approves Plenity from Gelesis Plenity is a new non-stimulant, non-systemic aid in weight management based on proprietary hydrogel technology. Dr. Reddy's to acquire generic injectables portfolio Dr. Reddy's is set to 42 products with a market value of roughly $645 million. NACDS' Anderson urges drug abuse prevention bill sensitive to chronic pain patients’ needs The Hill published a column by NACDS president and CEO Steve Anderson on a bill that would serve as a “safety” mechanism for the use of opioids in treating temporary, or acute, pain. Janssen's Balversa gets FDA nod Janssen's Balversa is the first personalized treatment targeting susceptible genetic alternations for patients with metastatic bladder cancer. NCPA's annual Congressional Fly-In tallied more than 600 Congressional visits The National Community Pharmacists Association-hosted Congressional Fly-In event drew hundreds of community pharmacists from 39 states. Zydus Cadila’s generic Xeljanz gets tentative approval Zydus Cadila's generic Xeljanz tablets are used to treat moderate to severe forms of rheumatoid arthritis. First Previous 521 522 523 524 525 Next Last
